Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction

Publisher Website
Google Scholar
Abstract
Safety and pharmacokinetic parameters of ceftazidime were evaluated in twelve male volunteers mean age 54 6±92 years. All had chronically impaired hepatic function which remained stable or normalized during ceftazidime administration There was neither nephrotoxicity nor haematological toxicity. Serum concentration time curves of ceftazidime exhibited a biexponential decline. Drug accumulation was not apparent. Following doses 4 and 13, mean serum half-lives were 2·8 and 2·9 h, volumes of distribution 015±0·04 I/kg and 0·17±0·041 l/kg and plasma clearance values 1·320±0·50 ml/min/kg and 1·096±0·48 ml/min/kg, respectively. Dose modification based on hepatic dysfunction is unnecessary.